董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert P. Mauch | 男 | Chief Executive Officer,Director and President | 59 | 1825.62万美元 | 11.45 | 2026-06-30 |
| Lorence H. Kim | 男 | Independent Director | 52 | 33.02万美元 | 0.02 | 2026-06-30 |
| Lori J. Ryerkerk | 女 | Independent Director | 63 | 19.24万美元 | 未持股 | 2026-06-30 |
| Dennis M. Nally | 男 | Independent Director | 73 | 34.57万美元 | 1.27 | 2026-06-30 |
| Lauren M. Tyler | 女 | Independent Director | 64 | 36.09万美元 | 0.04 | 2026-06-30 |
| Frank K. Clyburn | 男 | Independent Director | 61 | 39.64万美元 | 0.04 | 2026-06-30 |
| Redonda G. Miller | 女 | Independent Director | 59 | 38.52万美元 | 0.16 | 2026-06-30 |
| Werner Baumann | 男 | Independent Director | 63 | 38.31万美元 | 未持股 | 2026-06-30 |
| D. Mark Durcan | 男 | Director and Independent Chair | 65 | 37.52万美元 | 2.19 | 2026-06-30 |
| Lon R. Greenberg | 男 | Independent Director | 76 | 33.02万美元 | 1.71 | 2026-06-30 |
| Ellen G. Cooper | 女 | Independent Director | 61 | 未披露 | 未持股 | 2026-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert P. Mauch | 男 | Chief Executive Officer,Director and President | 59 | 1825.62万美元 | 11.45 | 2026-06-30 |
| Pawan Verma | 男 | Chief Data and Information Officer and Executive Vice President | 49 | 未披露 | 未持股 | 2026-06-30 |
| Lazarus Krikorian | -- | Senior Vice President and Chief Accounting Officer | -- | 未披露 | 未持股 | 2026-06-30 |
| Silvana Battaglia | 女 | Chief Human Resources Officer and Executive Vice President | 59 | 366.34万美元 | 2.05 | 2026-06-30 |
| Elizabeth S. Campbell | 女 | Chief Legal Officer and Executive Vice President | 52 | 517.67万美元 | 2.72 | 2026-06-30 |
董事简历
中英对照 | 中文 | 英文- Robert P. Mauch
-
Robert P. Mauch，自2024年10月起担任Cencora总裁兼首席执行官，并担任董事会成员。从2022年10月到2024年9月，Mauch先生担任Cencora的执行副总裁兼首席运营官，此前自2007年以来曾在Cencora及其前身担任过多个其他领导职务，包括领导Cencora的分销业务。他是Xcenda，L.L.C.的创始人，这是一家面向制药公司的生命科学商业化和咨询公司，Xcenda，L.L.C.于2007年被Cencora收购。Mauch先生还是卫生经济学和结果研究专业协会、美国管理式护理药房协会和美国药剂师协会的成员，以及费城盟约之家的董事会主席。
Robert P. Mauch has served as the President and Chief Executive Officer of Cencora and as a member of the Board since October 2024. From October 2022 through September 2024, Mr. Mauch was Executive Vice President and Chief Operating Officer of Cencora, and prior to that, he served in a variety of other leadership positions at Cencora and its predecessor since 2007, including time leading Cencora's distribution biness. He founded Xcenda, L.L.C., a life sciences commercialization and consulting firm to pharmaceutical companies, which was acquired by Cencora in 2007. Mr. Mauch is a member of the American Pharmacists Association, the American Society of Managed Care Pharmacy, and the Professional Society for Health Economics and Outcomes Research, and is Chairman of the Board of Directors of the Covenant Hoe of Philadelphia. - Robert P. Mauch，自2024年10月起担任Cencora总裁兼首席执行官，并担任董事会成员。从2022年10月到2024年9月，Mauch先生担任Cencora的执行副总裁兼首席运营官，此前自2007年以来曾在Cencora及其前身担任过多个其他领导职务，包括领导Cencora的分销业务。他是Xcenda，L.L.C.的创始人，这是一家面向制药公司的生命科学商业化和咨询公司，Xcenda，L.L.C.于2007年被Cencora收购。Mauch先生还是卫生经济学和结果研究专业协会、美国管理式护理药房协会和美国药剂师协会的成员，以及费城盟约之家的董事会主席。
- Robert P. Mauch has served as the President and Chief Executive Officer of Cencora and as a member of the Board since October 2024. From October 2022 through September 2024, Mr. Mauch was Executive Vice President and Chief Operating Officer of Cencora, and prior to that, he served in a variety of other leadership positions at Cencora and its predecessor since 2007, including time leading Cencora's distribution biness. He founded Xcenda, L.L.C., a life sciences commercialization and consulting firm to pharmaceutical companies, which was acquired by Cencora in 2007. Mr. Mauch is a member of the American Pharmacists Association, the American Society of Managed Care Pharmacy, and the Professional Society for Health Economics and Outcomes Research, and is Chairman of the Board of Directors of the Covenant Hoe of Philadelphia.
- Lorence H. Kim
-
Lorence H. Kim，曾任职Cencora， Inc.。自2022年10月起担任董事会成员，目前是Ascenta Capital的风险合伙人。从2020年9月到2022年12月，他担任Third Rock Ventures的风险合伙人。2014年4月至2020年6月，他担任Moderna， Inc.的首席财务官。2000年7月至2014年4月，他在Goldman， Sachs & Co.担任多个职位，最近担任生物技术投资银行董事总经理兼联席主管。他自2022年7月起担任Revolution Medicines， Inc.的董事，并自2022年2月起担任TD Cowen（前身为Cowen， Inc.）的董事。Kim博士目前是美国红十字会理事会的成员。2014年10月至2020年6月，他曾担任Seres Therapeutics的董事会成员。
Lorence H. Kim has served on the Board since October 2022 and currently is a Venture Partner at Ascenta Capital. Prior to founding Ascenta Capital in January 2023, he served as a Venture Partner at Third Rock Ventures from September 2020 to December 2022. He served as the Chief Financial Officer of Moderna, Inc. from April 2014 until June 2020. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently serving as Managing Director and Co Head, Biotechnology Investment Banking. Dr. Kim has served as a director of ADARx, Inc., since January 2023, as a director of Revolution Medicines, Inc., since July 2022, and as a director of TD Con (formerly known as Con, Inc. and now a subsidiary of TD Bank, N.A.) since February 2022. Dr. Kim is currently a member of the American Red Cross Board of Governors. He previoly served as a member of the Board of Directors of Seres Therapeutics, Inc. from October 2014 to June 2020. - Lorence H. Kim，曾任职Cencora， Inc.。自2022年10月起担任董事会成员，目前是Ascenta Capital的风险合伙人。从2020年9月到2022年12月，他担任Third Rock Ventures的风险合伙人。2014年4月至2020年6月，他担任Moderna， Inc.的首席财务官。2000年7月至2014年4月，他在Goldman， Sachs & Co.担任多个职位，最近担任生物技术投资银行董事总经理兼联席主管。他自2022年7月起担任Revolution Medicines， Inc.的董事，并自2022年2月起担任TD Cowen（前身为Cowen， Inc.）的董事。Kim博士目前是美国红十字会理事会的成员。2014年10月至2020年6月，他曾担任Seres Therapeutics的董事会成员。
- Lorence H. Kim has served on the Board since October 2022 and currently is a Venture Partner at Ascenta Capital. Prior to founding Ascenta Capital in January 2023, he served as a Venture Partner at Third Rock Ventures from September 2020 to December 2022. He served as the Chief Financial Officer of Moderna, Inc. from April 2014 until June 2020. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently serving as Managing Director and Co Head, Biotechnology Investment Banking. Dr. Kim has served as a director of ADARx, Inc., since January 2023, as a director of Revolution Medicines, Inc., since July 2022, and as a director of TD Con (formerly known as Con, Inc. and now a subsidiary of TD Bank, N.A.) since February 2022. Dr. Kim is currently a member of the American Red Cross Board of Governors. He previoly served as a member of the Board of Directors of Seres Therapeutics, Inc. from October 2014 to June 2020.
- Lori J. Ryerkerk
-
Lori J. Ryerkerk，是位于德克萨斯州达拉斯的财富500强全球化学和特种材料公司塞拉尼斯公司（Celanese Corp.）的前董事长、首席执行官和总裁。她于2019年加入塞拉尼斯，担任首席执行官，并于2020年成为董事长。在她的领导下，塞拉尼斯实现了显著增长，完成了变革性收购，并提升了行业领先的安全性能。Ryerkerk在能源行业的专业知识跨度超过30年。她曾担任壳牌下游公司（Shell Downstream Inc.）的全球制造执行副总裁，监督全球炼油厂和化学工厂的运营。在加入壳牌之前，她曾在Hess Corp.和ExxonMobil担任高级领导职务，在那里她获得了炼油、化学品和全球运营方面的丰富经验。她持有爱荷华州立大学（Iowa State University）的化学工程学位，目前担任Eaton Corp.（电力管理技术的领导者）的董事会成员。
Lori J. Ryerkerk,CELANESE CORP:President and Chief Executive Officer (2019 – 2024);SHELL CORP:Executive Vice President, Global Manufacturing (2013 – 2018),Regional Vice President Manufacturing, Europe and Africa (2010 – 2013);HESS CORP:Senior Vice President, Refining, Supply and Terminals (2008 – 2010);EXXONMOBIL:Manager, Government Relations and PA Business Support (2007 – 2008),Refinery Manager, Beaumont Refinery (2004 – 2007),Chairman, Managing Director, ExxonMobil Energy Ltd. (2002 – 2004),Various Ascending Positions (1984 – 2002). - Lori J. Ryerkerk，是位于德克萨斯州达拉斯的财富500强全球化学和特种材料公司塞拉尼斯公司（Celanese Corp.）的前董事长、首席执行官和总裁。她于2019年加入塞拉尼斯，担任首席执行官，并于2020年成为董事长。在她的领导下，塞拉尼斯实现了显著增长，完成了变革性收购，并提升了行业领先的安全性能。Ryerkerk在能源行业的专业知识跨度超过30年。她曾担任壳牌下游公司（Shell Downstream Inc.）的全球制造执行副总裁，监督全球炼油厂和化学工厂的运营。在加入壳牌之前，她曾在Hess Corp.和ExxonMobil担任高级领导职务，在那里她获得了炼油、化学品和全球运营方面的丰富经验。她持有爱荷华州立大学（Iowa State University）的化学工程学位，目前担任Eaton Corp.（电力管理技术的领导者）的董事会成员。
- Lori J. Ryerkerk,CELANESE CORP:President and Chief Executive Officer (2019 – 2024);SHELL CORP:Executive Vice President, Global Manufacturing (2013 – 2018),Regional Vice President Manufacturing, Europe and Africa (2010 – 2013);HESS CORP:Senior Vice President, Refining, Supply and Terminals (2008 – 2010);EXXONMOBIL:Manager, Government Relations and PA Business Support (2007 – 2008),Refinery Manager, Beaumont Refinery (2004 – 2007),Chairman, Managing Director, ExxonMobil Energy Ltd. (2002 – 2004),Various Ascending Positions (1984 – 2002).
- Dennis M. Nally
-
Dennis M. Nally于2020年1月加入董事会。2009年至2016年，他担任普华永道网络协调与治理实体普华永道会计师事务所主席。2002年至2009年，他担任美国董事长兼高级合伙人。 普华永道会计师事务所。 他于1974年加入普华永道会计师事务所（PricewaterhouseCoopers LLP），并于1985年成为合伙人，在组织内担任多个领导职务，包括国家战略计划总监，审计和业务咨询服务负责人以及执行合伙人。 Nally先生是Morgan Stanley and Globality，Inc.的董事会成员。
Dennis M. Nally has served on the Board since January 2020. He served as Chairman of PricewaterhoeCoopers International Ltd., the coordinating and governance entity of the PwC network, from 2009 to 2016. From 2002 to 2009, he served as Chairman and Senior Partner of the U.S. firm PricewaterhoeCoopers LLP. He joined PricewaterhoeCoopers LLP in 1974 and became partner in 1985, serving in numero leadership positions within the organization, including National Director of Strategic Planning, Audit and Biness Advisory Services Leader and Managing Partner. Mr. Nally is a member of the boards of Morgan Stanley and Globality, Inc., a privately held company. - Dennis M. Nally于2020年1月加入董事会。2009年至2016年，他担任普华永道网络协调与治理实体普华永道会计师事务所主席。2002年至2009年，他担任美国董事长兼高级合伙人。 普华永道会计师事务所。 他于1974年加入普华永道会计师事务所（PricewaterhouseCoopers LLP），并于1985年成为合伙人，在组织内担任多个领导职务，包括国家战略计划总监，审计和业务咨询服务负责人以及执行合伙人。 Nally先生是Morgan Stanley and Globality，Inc.的董事会成员。
- Dennis M. Nally has served on the Board since January 2020. He served as Chairman of PricewaterhoeCoopers International Ltd., the coordinating and governance entity of the PwC network, from 2009 to 2016. From 2002 to 2009, he served as Chairman and Senior Partner of the U.S. firm PricewaterhoeCoopers LLP. He joined PricewaterhoeCoopers LLP in 1974 and became partner in 1985, serving in numero leadership positions within the organization, including National Director of Strategic Planning, Audit and Biness Advisory Services Leader and Managing Partner. Mr. Nally is a member of the boards of Morgan Stanley and Globality, Inc., a privately held company.
- Lauren M. Tyler
-
LaurenM.Tyler自2015年以来一直担任摩根大通资产与财富管理公司（J.P.Morgan Asset&Wealth Management）的人力资源主管，负责人力资源的各个方面。在此之前，Tyler女士于2012年至2015年担任J.P.Morgan的全球首席审计师，并于2009年至2012年担任投资者关系主管。
Lauren M. Tyler has been Head of Human Resources at J.P. Morgan Asset & Wealth Management overseeing all aspects of human resources, since 2015. Prior to that, Ms. Tyler was Global Chief Auditor for J.P. Morgan from 2012 to 2015 and Head of Investor Relations from 2009 to 2012. - LaurenM.Tyler自2015年以来一直担任摩根大通资产与财富管理公司（J.P.Morgan Asset&Wealth Management）的人力资源主管，负责人力资源的各个方面。在此之前，Tyler女士于2012年至2015年担任J.P.Morgan的全球首席审计师，并于2009年至2012年担任投资者关系主管。
- Lauren M. Tyler has been Head of Human Resources at J.P. Morgan Asset & Wealth Management overseeing all aspects of human resources, since 2015. Prior to that, Ms. Tyler was Global Chief Auditor for J.P. Morgan from 2012 to 2015 and Head of Investor Relations from 2009 to 2012.
- Frank K. Clyburn
-
Frank K. Clyburn，自2024年10月起担任董事会成员。从2022年2月到2024年2月，他担任International Flavors & Fragrances Inc.的执行董事兼首席执行官。此前，他曾担任Merck & Co., Inc.（“Merck”）的执行副总裁兼人类健康总裁（从2021年3月到2022年1月）。从2008年到2021年，他在默克公司担任多种其他领导职务，包括领导公司的肿瘤学和市场准入业务。2004年至2008年，他担任赛诺菲安万特肿瘤学和内科副总裁，1994年以来，他担任赛诺菲安万特及其前身公司的各种职务。Clyburn先生自2024年8月起担任Revolution Medicines， Inc.的董事，此前曾担任DuPont de Numours， Inc.的董事会成员（2019年至2022年）。
Frank K. Clyburn has served on the Board since October 2024. He served as Executive Director and Chief Executive Officer of International Flavors & Fragrances Inc. from February 2022 to February 2024. Previoly Mr. Clyburn served as Executive Vice President and President, Human Health of Merck & Co., Inc. ("Merck") from March 2021 to January 2022. Mr. Clyburn held a variety of other leadership positions with Merck from 2008 to 2021, including leading the company's oncology and market access biness. Prior to Merck, Mr. Clyburn was Vice President, Oncology and Internal Medicine of Sanofi Aventis from 2004 to 2008 and held vario positions of increasing responsibility for Sanofi Aventis and its predecessors beginning in 1994. Mr. Clyburn has been a director of Revolution Medicines, Inc. since Augt 2024 and Kailera Therapeutics, a privately held company, since November 2025. He previoly served as a director of DuPont de Nems, Inc. from 2019 to 2022. - Frank K. Clyburn，自2024年10月起担任董事会成员。从2022年2月到2024年2月，他担任International Flavors & Fragrances Inc.的执行董事兼首席执行官。此前，他曾担任Merck & Co., Inc.（“Merck”）的执行副总裁兼人类健康总裁（从2021年3月到2022年1月）。从2008年到2021年，他在默克公司担任多种其他领导职务，包括领导公司的肿瘤学和市场准入业务。2004年至2008年，他担任赛诺菲安万特肿瘤学和内科副总裁，1994年以来，他担任赛诺菲安万特及其前身公司的各种职务。Clyburn先生自2024年8月起担任Revolution Medicines， Inc.的董事，此前曾担任DuPont de Numours， Inc.的董事会成员（2019年至2022年）。
- Frank K. Clyburn has served on the Board since October 2024. He served as Executive Director and Chief Executive Officer of International Flavors & Fragrances Inc. from February 2022 to February 2024. Previoly Mr. Clyburn served as Executive Vice President and President, Human Health of Merck & Co., Inc. ("Merck") from March 2021 to January 2022. Mr. Clyburn held a variety of other leadership positions with Merck from 2008 to 2021, including leading the company's oncology and market access biness. Prior to Merck, Mr. Clyburn was Vice President, Oncology and Internal Medicine of Sanofi Aventis from 2004 to 2008 and held vario positions of increasing responsibility for Sanofi Aventis and its predecessors beginning in 1994. Mr. Clyburn has been a director of Revolution Medicines, Inc. since Augt 2024 and Kailera Therapeutics, a privately held company, since November 2025. He previoly served as a director of DuPont de Nems, Inc. from 2019 to 2022.
- Redonda G. Miller
-
Redonda G. Miller，曾任职Cencora， Inc.。自2023年1月起担任董事会成员。她曾担任the Johns Hopkins Hospital的总裁（2016年以来）。此前，Miller博士曾担任The Johns Hopkins Hospital and Health System的首席医疗官兼医疗事务高级副总裁（2016年至2017年），以及The Johns Hopkins Hospital and Health System的首席医疗官兼医疗事务副总裁（2009年至2016年）。Miller博士自2006年起担任the Johns Hopkins University医学系副教授。从2021年11月到2022年10月，她担任Invivyd， Inc.（前身为Adagio Therapeutics， Inc.）的非执行董事。Miller博士是Gilchrist Hospice Care， Inc.的董事会成员，也是Turnaround Tuesday Inc.的董事会成员。
Redonda G. Miller has served on the Board since January 2023. She has served as the President of The Johns Hopkins Hospital since 2016. Previoly, Dr. Miller was Chief Medical Officer and Senior Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2016 to 2017, and Chief Medical Officer and Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2009 to 2016. Dr. Miller has been an associate professor in the Department of Medicine at The Johns Hopkins University since 2006. From November 2021 to October 2022, she served as a director of Invivyd, Inc. (formerly Adagio Therapeutics, Inc.). Dr. Miller is a member of the boards of Gilchrist Hospice Care, Inc. and Turnaround Tuesday Inc. - Redonda G. Miller，曾任职Cencora， Inc.。自2023年1月起担任董事会成员。她曾担任the Johns Hopkins Hospital的总裁（2016年以来）。此前，Miller博士曾担任The Johns Hopkins Hospital and Health System的首席医疗官兼医疗事务高级副总裁（2016年至2017年），以及The Johns Hopkins Hospital and Health System的首席医疗官兼医疗事务副总裁（2009年至2016年）。Miller博士自2006年起担任the Johns Hopkins University医学系副教授。从2021年11月到2022年10月，她担任Invivyd， Inc.（前身为Adagio Therapeutics， Inc.）的非执行董事。Miller博士是Gilchrist Hospice Care， Inc.的董事会成员，也是Turnaround Tuesday Inc.的董事会成员。
- Redonda G. Miller has served on the Board since January 2023. She has served as the President of The Johns Hopkins Hospital since 2016. Previoly, Dr. Miller was Chief Medical Officer and Senior Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2016 to 2017, and Chief Medical Officer and Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2009 to 2016. Dr. Miller has been an associate professor in the Department of Medicine at The Johns Hopkins University since 2006. From November 2021 to October 2022, she served as a director of Invivyd, Inc. (formerly Adagio Therapeutics, Inc.). Dr. Miller is a member of the boards of Gilchrist Hospice Care, Inc. and Turnaround Tuesday Inc.
- Werner Baumann
-
Werner Baumann，曾任职Cencora， Inc.。自2023年10月起担任董事会成员。他曾担任Bayer AG的首席执行官兼管理委员会主席（2016年5月至2023年5月退休），并于2020年1月至2023年5月担任首席可持续发展官。Baumann先生于1988年加入Bayer AG，并在公司担任多个职位，责任越来越大，包括在Bayer AG的管理委员会担任首席财务官（2010年至2014年）和首席战略和投资组合官（2014年至2016年）。
Werner Baumann has served on the Board since October 2023. He previoly served as Chief Executive Officer and Chairman of the Board of Management of Bayer AG from May 2016 until his retirement in May 2023, and as Chief Stainability Officer from January 2020 to May 2023. Mr. Baumann joined Bayer AG in 1988 and held numero positions of increasing responsibility at the company, including positions on the Board of Management of Bayer AG as Chief Financial Officer from 2010 to 2014 and Chief Strategy and Portfolio Officer from 2014 to 2016. - Werner Baumann，曾任职Cencora， Inc.。自2023年10月起担任董事会成员。他曾担任Bayer AG的首席执行官兼管理委员会主席（2016年5月至2023年5月退休），并于2020年1月至2023年5月担任首席可持续发展官。Baumann先生于1988年加入Bayer AG，并在公司担任多个职位，责任越来越大，包括在Bayer AG的管理委员会担任首席财务官（2010年至2014年）和首席战略和投资组合官（2014年至2016年）。
- Werner Baumann has served on the Board since October 2023. He previoly served as Chief Executive Officer and Chairman of the Board of Management of Bayer AG from May 2016 until his retirement in May 2023, and as Chief Stainability Officer from January 2020 to May 2023. Mr. Baumann joined Bayer AG in 1988 and held numero positions of increasing responsibility at the company, including positions on the Board of Management of Bayer AG as Chief Financial Officer from 2010 to 2014 and Chief Strategy and Portfolio Officer from 2014 to 2016.
- D. Mark Durcan
-
D. Mark Durcan，曾在Cencora， Inc.任职。自2015年9月起担任董事会主席，自2023年3月起担任首席独立董事。他曾担任Micron Technology， Inc.的首席执行官兼董事（2012年2月至2017年5月退休）。Durcan先生从2007年6月到2012年2月担任Micron Technology， Inc.的总裁兼首席运营官，从2006年2月到2007年6月担任首席运营官，从1997年6月到2006年2月担任首席技术官。1984年至2006年2月，他担任Micron Technology， Inc.及其子公司的各种其他职位，并从1996年到退休担任官员。他曾担任MWI Veterinary Supply， Inc.的董事（从2014年3月到2015年2月被AmerisourceBergen收购）。Durcan先生自2017年10月起担任Advanced Micro Devices的董事，自2020年4月起担任ASML Holding NV的董事。他曾于2018年4月至2022年4月担任Veoneer的董事，并于2014年至2015年担任Freescale Semiconductor， Inc.的董事。Durcan先生自2017年2月起担任爱达荷州St. Luke's Health System的董事，并自2020年6月起担任Rice大学的董事会成员。他还曾任职于半导体行业协会董事会和技术首席执行官委员会。
D. Mark Durcan was appointed as a member of the Supervisory Board in 2020. He is Chair of the Board of Directors at Cencora since October 1 , 2025. He is also a member of the Board of Trtees for Rice University (Texas) and as Director at Natural Intelligence Systems CA, a private Al startup company. From 2012 to 2017, he was CEO of Micron Technology, Inc., having joined the company in 1984 and having held vario management positions before being appointed CEO. Furthermore, Mark was a non executive director of Advanced Micro Devices, Inc., and a director at Freescale Semiconductor, MWI Veterinary Supply, Veoneer, Inc. - D. Mark Durcan，曾在Cencora， Inc.任职。自2015年9月起担任董事会主席，自2023年3月起担任首席独立董事。他曾担任Micron Technology， Inc.的首席执行官兼董事（2012年2月至2017年5月退休）。Durcan先生从2007年6月到2012年2月担任Micron Technology， Inc.的总裁兼首席运营官，从2006年2月到2007年6月担任首席运营官，从1997年6月到2006年2月担任首席技术官。1984年至2006年2月，他担任Micron Technology， Inc.及其子公司的各种其他职位，并从1996年到退休担任官员。他曾担任MWI Veterinary Supply， Inc.的董事（从2014年3月到2015年2月被AmerisourceBergen收购）。Durcan先生自2017年10月起担任Advanced Micro Devices的董事，自2020年4月起担任ASML Holding NV的董事。他曾于2018年4月至2022年4月担任Veoneer的董事，并于2014年至2015年担任Freescale Semiconductor， Inc.的董事。Durcan先生自2017年2月起担任爱达荷州St. Luke's Health System的董事，并自2020年6月起担任Rice大学的董事会成员。他还曾任职于半导体行业协会董事会和技术首席执行官委员会。
- D. Mark Durcan was appointed as a member of the Supervisory Board in 2020. He is Chair of the Board of Directors at Cencora since October 1 , 2025. He is also a member of the Board of Trtees for Rice University (Texas) and as Director at Natural Intelligence Systems CA, a private Al startup company. From 2012 to 2017, he was CEO of Micron Technology, Inc., having joined the company in 1984 and having held vario management positions before being appointed CEO. Furthermore, Mark was a non executive director of Advanced Micro Devices, Inc., and a director at Freescale Semiconductor, MWI Veterinary Supply, Veoneer, Inc.
- Lon R. Greenberg
-
Lon R. Greenberg，自2013年5月起在Cencora，Inc.董事会任职。他于1996年至2016年1月期间担任UGI公司董事会主席，并担任UGI Utilities，Inc.和AmeriGas Propane的董事，这两家公司均为UGI Corporation的子公司。Greenberg先生自1995年起担任UGI公司的首席执行官，直至2013年4月退休。Greenberg先生在UGI公司任职期间曾担任多个领导职务。格林伯格先生是天普大学董事会成员和费城基金会董事会成员。他还担任天普大学卫生系统董事会主席。他此前曾担任Aqua America，Inc.（现名Essential Utilities, Inc.）、Ameriprise Financial, Inc.、Fox Chase癌症中心以及大费城和新泽西州南部联合之路的董事会成员。
Lon R. Greenberg has served on the Board since May 2013. He served as Chairman of UGI Corporation's Board of Directors from 1996 until January 2016 and as director of UGI Utilities, Inc. and AmeriGas Propane, both UGI Corporation subsidiaries. Mr. Greenberg served in vario leadership positions throughout his tenure with UGI Corporation, most recently serving as Chief Executive Officer from 1995 until his retirement in April 2013. Mr. Greenberg is a member of the Board of Trtees of Temple University and the Board of Directors of The Philadelphia Foundation. He also serves as Chairman of the Board of Directors of Temple University Health System. He previoly served as a director of Aqua America, Inc. (now known as Essential Utilities, Inc.), Ameriprise Financial, Inc., Fox Chase Cancer Center, and the United Way of Greater Philadelphia and Southern New Jersey. - Lon R. Greenberg，自2013年5月起在Cencora，Inc.董事会任职。他于1996年至2016年1月期间担任UGI公司董事会主席，并担任UGI Utilities，Inc.和AmeriGas Propane的董事，这两家公司均为UGI Corporation的子公司。Greenberg先生自1995年起担任UGI公司的首席执行官，直至2013年4月退休。Greenberg先生在UGI公司任职期间曾担任多个领导职务。格林伯格先生是天普大学董事会成员和费城基金会董事会成员。他还担任天普大学卫生系统董事会主席。他此前曾担任Aqua America，Inc.（现名Essential Utilities, Inc.）、Ameriprise Financial, Inc.、Fox Chase癌症中心以及大费城和新泽西州南部联合之路的董事会成员。
- Lon R. Greenberg has served on the Board since May 2013. He served as Chairman of UGI Corporation's Board of Directors from 1996 until January 2016 and as director of UGI Utilities, Inc. and AmeriGas Propane, both UGI Corporation subsidiaries. Mr. Greenberg served in vario leadership positions throughout his tenure with UGI Corporation, most recently serving as Chief Executive Officer from 1995 until his retirement in April 2013. Mr. Greenberg is a member of the Board of Trtees of Temple University and the Board of Directors of The Philadelphia Foundation. He also serves as Chairman of the Board of Directors of Temple University Health System. He previoly served as a director of Aqua America, Inc. (now known as Essential Utilities, Inc.), Ameriprise Financial, Inc., Fox Chase Cancer Center, and the United Way of Greater Philadelphia and Southern New Jersey.
- Ellen G. Cooper
-
Ellen G. Cooper自2026年1月20日起在董事会任职，现任林肯国民集团公司（“林肯”）董事长、总裁兼首席执行官。Cooper女士于2012年加入林肯，2012年至2022年担任执行副总裁、首席投资官、企业风险和年金解决方案负责人。她于2022年5月成为首席执行官，并于2023年5月担任董事长。在加入林肯之前，Cooper女士曾在高盛资产管理公司担任董事总经理兼全球保险战略主管，在AEGON Americas担任首席风险官，在Ernst & Young LLP担任负责人。她的职业生涯始于Tors Perrin的保险咨询。她是精算师协会会员和特许企业风险分析师，以及特许金融分析师（CFA）特许持有人。她目前担任美国人寿保险公司理事会执行委员会和天普大学Trtees董事会成员。
Ellen G. Cooper has served on the Board since January 20, 2026, and currently is Chairman, President and CEO of Lincoln National Corporation ("Lincoln"). Ms. Cooper joined Lincoln in 2012, serving as Executive Vice President, Chief Investment Officer, Head of Enterprise Risk and Annuity Solutions from 2012 to 2022. She became CEO in May 2022 and assumed the role of Chairman in May 2023. Prior to joining Lincoln, Ms. Cooper served as Managing Director and Head of Global Insurance Strategy at Goldman Sachs Asset Management, as Chief Risk Officer of AEGON Americas, and as a Principal at Ernst & Young LLP. She began her career in insurance consulting at Tors Perrin. She is a Fellow of the Society of Actuaries and a Chartered Enterprise Risk Analyst, as ll as a Chartered Financial Analyst (CFA) charterholder. She currently serves on the Executive Committee of the American Council of Life Insurers and the Board of Trtees of Temple University. - Ellen G. Cooper自2026年1月20日起在董事会任职，现任林肯国民集团公司（“林肯”）董事长、总裁兼首席执行官。Cooper女士于2012年加入林肯，2012年至2022年担任执行副总裁、首席投资官、企业风险和年金解决方案负责人。她于2022年5月成为首席执行官，并于2023年5月担任董事长。在加入林肯之前，Cooper女士曾在高盛资产管理公司担任董事总经理兼全球保险战略主管，在AEGON Americas担任首席风险官，在Ernst & Young LLP担任负责人。她的职业生涯始于Tors Perrin的保险咨询。她是精算师协会会员和特许企业风险分析师，以及特许金融分析师（CFA）特许持有人。她目前担任美国人寿保险公司理事会执行委员会和天普大学Trtees董事会成员。
- Ellen G. Cooper has served on the Board since January 20, 2026, and currently is Chairman, President and CEO of Lincoln National Corporation ("Lincoln"). Ms. Cooper joined Lincoln in 2012, serving as Executive Vice President, Chief Investment Officer, Head of Enterprise Risk and Annuity Solutions from 2012 to 2022. She became CEO in May 2022 and assumed the role of Chairman in May 2023. Prior to joining Lincoln, Ms. Cooper served as Managing Director and Head of Global Insurance Strategy at Goldman Sachs Asset Management, as Chief Risk Officer of AEGON Americas, and as a Principal at Ernst & Young LLP. She began her career in insurance consulting at Tors Perrin. She is a Fellow of the Society of Actuaries and a Chartered Enterprise Risk Analyst, as ll as a Chartered Financial Analyst (CFA) charterholder. She currently serves on the Executive Committee of the American Council of Life Insurers and the Board of Trtees of Temple University.
高管简历
中英对照 | 中文 | 英文- Robert P. Mauch
Robert P. Mauch，自2024年10月起担任Cencora总裁兼首席执行官，并担任董事会成员。从2022年10月到2024年9月，Mauch先生担任Cencora的执行副总裁兼首席运营官，此前自2007年以来曾在Cencora及其前身担任过多个其他领导职务，包括领导Cencora的分销业务。他是Xcenda，L.L.C.的创始人，这是一家面向制药公司的生命科学商业化和咨询公司，Xcenda，L.L.C.于2007年被Cencora收购。Mauch先生还是卫生经济学和结果研究专业协会、美国管理式护理药房协会和美国药剂师协会的成员，以及费城盟约之家的董事会主席。
Robert P. Mauch has served as the President and Chief Executive Officer of Cencora and as a member of the Board since October 2024. From October 2022 through September 2024, Mr. Mauch was Executive Vice President and Chief Operating Officer of Cencora, and prior to that, he served in a variety of other leadership positions at Cencora and its predecessor since 2007, including time leading Cencora's distribution biness. He founded Xcenda, L.L.C., a life sciences commercialization and consulting firm to pharmaceutical companies, which was acquired by Cencora in 2007. Mr. Mauch is a member of the American Pharmacists Association, the American Society of Managed Care Pharmacy, and the Professional Society for Health Economics and Outcomes Research, and is Chairman of the Board of Directors of the Covenant Hoe of Philadelphia.- Robert P. Mauch，自2024年10月起担任Cencora总裁兼首席执行官，并担任董事会成员。从2022年10月到2024年9月，Mauch先生担任Cencora的执行副总裁兼首席运营官，此前自2007年以来曾在Cencora及其前身担任过多个其他领导职务，包括领导Cencora的分销业务。他是Xcenda，L.L.C.的创始人，这是一家面向制药公司的生命科学商业化和咨询公司，Xcenda，L.L.C.于2007年被Cencora收购。Mauch先生还是卫生经济学和结果研究专业协会、美国管理式护理药房协会和美国药剂师协会的成员，以及费城盟约之家的董事会主席。
- Robert P. Mauch has served as the President and Chief Executive Officer of Cencora and as a member of the Board since October 2024. From October 2022 through September 2024, Mr. Mauch was Executive Vice President and Chief Operating Officer of Cencora, and prior to that, he served in a variety of other leadership positions at Cencora and its predecessor since 2007, including time leading Cencora's distribution biness. He founded Xcenda, L.L.C., a life sciences commercialization and consulting firm to pharmaceutical companies, which was acquired by Cencora in 2007. Mr. Mauch is a member of the American Pharmacists Association, the American Society of Managed Care Pharmacy, and the Professional Society for Health Economics and Outcomes Research, and is Chairman of the Board of Directors of the Covenant Hoe of Philadelphia.
- Pawan Verma
Pawan Verma自2015年8月10日起曾担任高级副总裁兼首席信息官。2013年2月至2015年7月，Verma先生在Target Corporation担任各种技术领导职务，在公司架构、电子商务、移动和数字化服务。他最近担任Digital Technology 和API Platforms的副总裁。2011年3月至2013年1月，他担任Convergys公司的电子商务、数字和手机的高级总监。2003年10月至2011年2月，他还担任过在Verizon Wireless各种技术领导职务。
Pawan Verma has served as Executive Vice President, Chief Information and Customer Connectivity Officer since October 2017 and as Senior Vice President and Chief Information Officer from August 2015 to September 2017. From February 2013 to July 2015 Mr. Verma served in various technology leadership roles at Target Corporation within enterprise architecture, e-commerce, mobile, and digital, with his most recent role as Vice President - Digital Technology and API Platforms.- Pawan Verma自2015年8月10日起曾担任高级副总裁兼首席信息官。2013年2月至2015年7月，Verma先生在Target Corporation担任各种技术领导职务，在公司架构、电子商务、移动和数字化服务。他最近担任Digital Technology 和API Platforms的副总裁。2011年3月至2013年1月，他担任Convergys公司的电子商务、数字和手机的高级总监。2003年10月至2011年2月，他还担任过在Verizon Wireless各种技术领导职务。
- Pawan Verma has served as Executive Vice President, Chief Information and Customer Connectivity Officer since October 2017 and as Senior Vice President and Chief Information Officer from August 2015 to September 2017. From February 2013 to July 2015 Mr. Verma served in various technology leadership roles at Target Corporation within enterprise architecture, e-commerce, mobile, and digital, with his most recent role as Vice President - Digital Technology and API Platforms.
- Lazarus Krikorian
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Silvana Battaglia
Silvana Battaglia自2019年1月以来一直担任执行副总裁兼首席人力资源官。在加入公司之前，她于2017年8月至2018年12月在Aramark担任全球薪酬，福利和劳资关系高级副总裁以及高级副总裁。于2011年5月至2017年8月担任全球现场人力资源总监。她还曾在Day＆Zimmerman和Merck Corporation工作。
Silvana Battaglia has been Executive Vice President and Chief Human Resces Officer since January 2019. Prior to joining the Company, she worked at Aramark as Senior Vice President of Global Compensation, Benefits, and Labor Relations from Augt 2017 to December 2018 and as Senior Vice President, Global Field Human Resces from May 2011 to Augt 2017. She also previoly worked for Day & Zimmerman and Merck Corporation.- Silvana Battaglia自2019年1月以来一直担任执行副总裁兼首席人力资源官。在加入公司之前，她于2017年8月至2018年12月在Aramark担任全球薪酬，福利和劳资关系高级副总裁以及高级副总裁。于2011年5月至2017年8月担任全球现场人力资源总监。她还曾在Day＆Zimmerman和Merck Corporation工作。
- Silvana Battaglia has been Executive Vice President and Chief Human Resces Officer since January 2019. Prior to joining the Company, she worked at Aramark as Senior Vice President of Global Compensation, Benefits, and Labor Relations from Augt 2017 to December 2018 and as Senior Vice President, Global Field Human Resces from May 2011 to Augt 2017. She also previoly worked for Day & Zimmerman and Merck Corporation.
- Elizabeth S. Campbell
Elizabeth S. Campbell于2021年9月被任命为Amerisourcebergen Corporation执行副总裁兼首席法律官。她于2020年6月至2021年8月担任高级副总裁和副总法律顾问。在此之前，Campbell女士曾在Amerisourcebergen Corporation法律部门担任各种职务，并承担更多责任，包括担任首席诉讼人和首席合规顾问。
Elizabeth S. Campbell has been Executive Vice President and Chief Legal Officer since September 2021. She served as Senior Vice President and Deputy General Counsel from June 2020 to August 2021. Prior to that, Ms. Campbell served in a variety of roles within the Company's legal department with increased responsibility, including serving as Chief Litigator and Chief Compliance Counsel. Ms. Campbell has been employed by the Company for 15 years.- Elizabeth S. Campbell于2021年9月被任命为Amerisourcebergen Corporation执行副总裁兼首席法律官。她于2020年6月至2021年8月担任高级副总裁和副总法律顾问。在此之前，Campbell女士曾在Amerisourcebergen Corporation法律部门担任各种职务，并承担更多责任，包括担任首席诉讼人和首席合规顾问。
- Elizabeth S. Campbell has been Executive Vice President and Chief Legal Officer since September 2021. She served as Senior Vice President and Deputy General Counsel from June 2020 to August 2021. Prior to that, Ms. Campbell served in a variety of roles within the Company's legal department with increased responsibility, including serving as Chief Litigator and Chief Compliance Counsel. Ms. Campbell has been employed by the Company for 15 years.